Landos Biopharma (Landos Biopharma) Total Inventories : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma Total Inventories?

Landos Biopharma's total inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Landos Biopharma's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Landos Biopharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $10.03.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Landos Biopharma Total Inventories Historical Data

The historical data trend for Landos Biopharma's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma Total Inventories Chart

Landos Biopharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

Landos Biopharma Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial														-	-	-	-	-

Landos Biopharma Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Landos Biopharma (NAS:LABP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Landos Biopharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(37.499	+	0.75 * 0	+	0.5 * 0	-	6.249
-	0	-	0)	/	3.11673
=	10.03

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Landos Biopharma's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Landos Biopharma's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Landos Biopharma's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Landos Biopharma Total Inventories Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Landos Biopharma (Landos Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 11239, Blacksburg, VA, USA, 24060

Website

https://www.landosbiopharma.com

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.

Executives

Alka Batycky	director	C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi	officer: Chief Medical Officer	C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes	director, officer: Chief Executive Officer	760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell	officer: Vice President and Controller	C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera	director, 10 percent owner, officer: Chairman, President and CEO	1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar	officer: Interim CFO	C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori	director	100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003